Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Russia's Ministry of Health approves the phase III clinical trial of the COVID-19 vaccine V-01 developed by CSPC Pharmaceutical Group

Published Time:

2021-11-11

On November 8, the website of the Russian Ministry of Health's National Research License Registry announced that the Ministry of Health has issued a license approving the phase III clinical trial of "Recombinant Novel Coronavirus Fusion Protein Vaccine" (V-01) developed by Livzon Mabpharm Inc. in Zhuhai, China. That is, a "randomized, double-blind, placebo-controlled, international multicenter phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of the recombinant novel coronavirus (SARS-CoV-2) fusion protein vaccine (V-01) in adults aged 18 and above."
 

Currently, the international multicenter, randomized, double-blind, placebo-controlled phase III clinical trial of V-01 in Pakistan and Malaysia is evaluating the protective efficacy, safety, and immunogenicity of V-01 as a booster dose in healthy adults aged 18 and above who have completed two doses of inactivated vaccine. Phase III clinical trials in the Philippines and Indonesia are also underway. The approval of this phase III clinical trial in Russia will further accelerate the development of V-01 and contribute Livzon's strength to the fight against the epidemic.

 

V-01 is an innovative novel coronavirus recombinant protein vaccine jointly developed by Livzon Mabpharm and the Institute of Biophysics, Chinese Academy of Sciences. V-01 was initiated in July 2020 and approved for clinical trials by the National Medical Products Administration of China in early 2021. The indication is for the prevention of diseases caused by novel coronavirus infection (COVID-19).

 

The domestic phase II clinical trial results of V-01 are as follows: (1) A phase II clinical trial of V-01 was conducted in people aged 18 and above, with a total of 880 subjects enrolled, including 440 in the adult group (18 to 59 years old) and 440 in the elderly group (≥60 years old) (the oldest being 83 years old); (2) The purpose of the trial was to preliminarily evaluate the safety and immunogenicity of the trial vaccine; (3) The trial results showed that in terms of safety, the incidence of adverse events related to the trial vaccine was low, and the severity of adverse reactions was mild (mostly grade 1), short in duration, and most resolved spontaneously within 1-3 days. No vaccine-related serious adverse events or adverse events requiring special attention were observed. In terms of immunogenicity, 14 days after two doses of vaccination according to the 0, 21-day schedule, the seroconversion rate of neutralizing antibodies in the entire population in the target dose vaccine group reached more than 97%. Vaccine recipients in both the adult and elderly groups were able to rapidly produce high titers of neutralizing antibodies, and there was no significant difference in neutralizing antibody titers between the elderly and adult groups; (4) The results of the domestic phase II clinical trial of V-01 demonstrated that V-01 has good safety and immunogenicity in the population that meets the criteria of this clinical trial protocol and can proceed to the next clinical trial. The data from the domestic phase I and phase II clinical trials of V-01 were published in Emerging Microbes & Infections and the Chinese Medical Journal (English edition) in July 2021, respectively.